April 17–22, 2026 · San Diego · 2418 items
← Medicinal chemistry beyond KRAS: CDK2, WEE1, SERD
4 people · 4 posts · 1 abstract
CID-078 is a cyclin A/B macrocycle; Circle Pharma reported early activity and acceptable safety at AACR.
Afshin Dowlati, Timothy A Yap, Antonio Giordano, Nehal J. Lakhani, William B McKean, Ildefonso Ismael Rodriguez Rivera, Vivek Subbiah, Kyaw Zin Thein, Judy S. Wang, Jinshu Fang, Li-Fen Liu, Peadar Cremin, Lukas Makris, Li-Pen Tsao, Lisa M. Kopp, Shivaani Kummar
Read the abstract →Circle Pharma raised a $92.5 million series E, announced Sept. 16, to advance preclinical cyclin D1 inhibitor CID-165 toward a planned clinical start in early 2027, making it the company's top priority over cyclin A/B inhibitor CID-078, which continues in Phase I. CEO David Earp said preclinical combination data drove the decision, with the aim of producing deeper responses in ER-positive breast cancer.
Why it matters: Series E funding reprioritizes pipeline, moving a preclinical program ahead of the clinical lead.
Four investigational drugs disclosed: CID-078 (Circle Pharma), AMX-883 (Amphista), JNJ-89862175 (Johnson & Johnson) and IPN01203 (Ipsen).